RxDoctor Payments Data

Amanda Shukla, DO

Internal Medicine · Union City, NJNPI 1346629227

Payments from drug & device makers

$3,047in general payments, 2019–2025

Across 91 payments — averaging $33.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$655
  • Amgen$418
  • Johnson & Johnson$249
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$235
  • AbbVie$171
  • Stryker$167
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,03199%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,047 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$108,295
Medicare patients
170
Services billed
965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$19,915
RexultiBrexpiprazole12$5,913
JardianceEmpagliflozin12$5,090
Pantoprazole Sodium50$4,420
JanuviaSitagliptin Phosphate16$3,524
NamzaricMemantine Hcl/Donepezil Hcl14$3,402
FarxigaDapagliflozin Propanediol16$2,822
LokelmaSodium Zirconium Cyclosilicate30$2,501
Gabapentin75$2,103
Lacosamide27$1,252
Atorvastatin Calcium66$1,212
Mirtazapine35$1,193
Duloxetine Hcl14$1,072
Divalproex Sodium44$942
LantusInsulin Glargine,hum.Rec.Anlog12$874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$19,91568 claims
AstraZenecaFarxiga, Lokelma$655$5,32346 claims
AbbVieNamzaric$171$3,40214 claims
Lilly USA, LLCInsulin Lispro$53$36412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Union City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →